The EC has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat CIDP.

David W Miller, CEO of Genesis Research Group, discusses how pharma's decade-long development approach is no longer fit for ...

Nicole Verdun, a highly respected individual in the cell and gene therapy space, was placed on administrative leave this week ...

Health Canada has granted a notice of compliance for Novartis Canada’s Kisqali (ribociclib tablets) plus an aromatase ...

NextCure has entered a strategic partnership with Simcere Zaiming, to develop SIM0505, a new ADC targeting CDH6 for treating ...

Revenue for Madrigal’s Rezdiffra, already approved in the US, is expected to skyrocket over the coming decade.

Orion Corporation has broadened its partnership with Glykos, focusing on the development of antibody-drug conjugates (ADCs).

Novo Nordisk has taken initiatives to accelerate target discovery by implementing AI/ML technologies into genetic and ...

Teva Pharmaceutical has announced a collaboration with Fosun Pharma to advance the global development of the ATTENUKINE ...

Lisata Therapeutics has formed a strategic partnership with GATC Health for advancing AI-driven drug discovery and ...

The NSW government has announced an investment of A$20.7m ($13.39m) aimed at providing access to life-changing therapies.

Actio Biosciences has closed a Series B financing round, raising $66m for advancing the genetics-driven small molecule ...